At #ASH25, @tamaciro shared updated results from the Phase II RESTORE trial evaluating elritercept in combination with ruxolitinib in patients with #myelofibrosis and anemia.

Find out more by clicking here:

👉 👈

#MPNsm #TrialUpdate #CTSM #HemOnc

Updates from the RESTORE trial of elritercept plus ruxolitinib in patients with MF and anemia

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, discusses the updated results from the Phase II RESTORE...

ow.ly

It was great to speak with @LuskinMarlise of @DanaFarber at #ASH25, who discussed a Phase I study that combined venetoclax and inotuzumab ozogamicin for the treatment of R/R ALL.🩸

Click here to watch: 👉

#ALLsm #Leusm #HemOnc #ImmunoOnc #CTSM

A Phase I study of venetoclax plus inotuzumab ozogamicin for R/R ALL

Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT05016947) that combi...

ow.ly

In a recent interview, @MattReesMD provided insight into a multicenter retrospective study assessing the safety & efficacy of BCMA-directed CAR-T in patients with systemic AL #amyloidosis & concurrent #MultipleMyeloma.

Watch it here: 👉

#MMSM #Myeloma

Evaluating the real-world safety and efficacy of BCMA-directed CAR-T in systemic AL amyloidosis

Matthew Rees, MD, St. Vincent's Hospital, Melbourne, Australia, provides insight into a multicenter retrospective study ...

ow.ly

Want to hear about a trial investigating huCART19-IL18, an IL18-armored CAR T-cell product, in patients with CLL/SLL and Richter’s transformation?💉🩸

Watch our interview from #ASH25 with Jakub Svoboda of @PennMedicine here:

👉 👈

#CLLsm #Leusm #CTSM

huCART19-IL18 in patients with CLL/SLL or RT after prior BTK inhibitor and venetoclax exposure

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, provides insight into a trial ...

ow.ly